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doi:10.1016/j.jfma.2011.05.016Objectives: Our aim was to investigate how transcatheter arterial chemoembolization (TACE)
combined with percutaneous radiofrequency ablation (RFA) affected liver parenchymal func-
tion in patients with hepatocellular carcinoma (HCC), and to evaluate the significant risk
factors for post-procedural deterioration of liver function.
Methods: Changes in liver laboratory tests and development of complications were monitored
in 53 patients with unresectable hepatocellular carcinoma from January 2007 to January 2009.
Cox proportional hazard regression model was performed to evaluate risk factors for deterio-
ration of liver function after the procedure.
Results: Plasma total bilirubin (TB) increased from pre-procedural 22.1  12.4 mmol/L to
34.1  21.8 mmol/L on post-procedural day three (P Z 0.017). Alanine aminotransferase
(ALT) also increased greatly from 65  58 IU/L to 285  182 IU/L post-procedurally
(P Z 0.006). Albumin (ALB) dropped from 42.5  4.5 g/L to 34.6  5.4 g/L (P Z 0.019) and
the ChildePugh score increased from 5.2  1.3 to 7.1  1.5 three days after treatment
(P Z 0.021). Most of these parameters returned to normal range within 3e4 weeks. Thirty-
three out of 53 patients developed complications in our study. Cox proportional hazards
regression univariate analysis demonstrated that a ChildePugh score 9 points and age 60
years were risk factors for deterioration of liver function after the procedure. Furthermore,
a ChildePugh score 9 points was found to be the only risk factor for post-procedural deteri-
oration of liver function identified by stepwise multivariate analysis.of Hepato-Bilio-Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
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Transcatheter arterial chemoembolization and radiofrequency ablation 511Conclusion: Liver function parameters such as plasma total bilirubin, ALT, serum ALB and
ChildePugh score could be transiently deteriorated by TACE combined with RFA in patients
with ChildePugh grades B or C. Therefore, patients with a ChildePugh score 9 points were
not appropriate candidates for TACE combined with RFA.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) ranks fifth among the most
common malignant tumors in the world and its incidence
is increasing.1e4 Although great improvements have been
made in the diagnosis of patients with early HCC by imaging
modalities, most are diagnosed at intermediate or
advanced stages, in which case less than 30% of patients can
undergo curative therapies such as hepatectomy or liver
transplantation.5,6 Patients with multiple HCC tumors,
recurrent tumors, or serious chronic liver disorders are not
suitable for resection and, in response to critical organ
shortage, many patients have to wait on the liver trans-
plantation list while some may move into an advanced
carcinoma stage during the waiting period. Therefore,
locoregional therapies such as percutaneous ethanol
injection (PEI), radiofrequency ablation (RFA), microwave
coagulation therapy, transcatheter arterial chemo-
embolization (TACE) and laser ablation are being used to
treat unresectable HCC, and these treatments are often
associated with a satisfactory long-term prognosis.7e10
Biochemical changes of liver function occur in patients
after resection, RFA or TACE. Needham et al studied
changes of postoperative biochemical liver function after
major hepatic resection and established normal profiles
of standard biochemical liver function tests after major
liver resection in noncirrhotic patients.11 Kuroda et al
investigated the changes in liver function parameters after
percutaneous RFA and drew a conclusion that a ChildePugh
score of nine or more represented a major risk factor for the
aggravation of liver function after RFA therapy.12 Kawaoka
et al studied the changes of liver function in patients after
TACE.13 Our study aims to investigate the changes of liver
parenchymal function and clarify risk factors for aggrava-
tion of liver function after TACE combined with RFA.Patients and methods
Patients
From January 2007 to January 2009, 53 patients with unre-
sectable hepatocellular carcinoma were reviewed in our
center. Inclusion criteria were as follows: (1) severe cirrhosis
indicating high risk of liver failure after resection (severe
cirrhosis comprehensively evaluated by ChildePugh grade B
or C, indocyanine green retention at 15 min (ICG-R15) 20%
or ultrasound/Computed Tomography (CT scan); (2) tumors
located at least 0.5 cm away from a great vessel, the gall-
bladder, or the common bile duct and 1 cm away from the
gastrointestinal tract; (3) tumor size <6.0 cm and number of
tumor is <5; (4) absence of tumor thrombus in the mainportal/hepatic trunk; (5) absence of extrahepatic metas-
tasis; (6) RFA was performed within one week after TACE; (7)
patients preferred mini-invasive therapies such as RFA or
TACE instead of resection; (8) HBV-DNA <104 copies/mL. All
53 patients met the inclusion criteria, of which five were on
the waiting list for liver transplantation. Baseline charac-
teristics of patients at the time of pretreatment for HCC
were shown in Table 1. In accordance with the Helsinki
declaration, informed consent was obtained from each
patient before treatment.
Transcatheter arterial chemoembolization (TACE)
Transcatheter arterial chemoembolization was performed
through the femoral artery under local anesthesia using the
technique of Seldinger. After the introduction of a 5-F
pigtail catheter through the femoral artery, an angio-
graphic survey of the abdominal vessels was performed.13
Depending on the location, size and arterial supply of the
tumor and its satellite lesions, the tip of the catheter was
directed toward tumor-feeding arteries for superselective
embolization of all tumors detected by digital subtraction
angiography. Next, emulsified suspension consisting of
50e100 mg of cisplatin, 2e8 mg of mitomycin C, 5e10 mg of
epirubicin and 10e20 mL of lipiodol was slowly injected
into tumor vessels under fluoroscopic guidance and fol-
lowed by embolization of gelatin sponge. However, gelatin
sponge was not used on the proper hepatic artery or right
hepatic artery due to its high risk of liver failure in cirrhotic
patients.
Radiofrequency ablation (RFA)
Radiofrequency ablation was achieved under general
anesthesia by employing a percutaneous approach guided
by ultrasonography (Vivid4 GE Corp, USA). Radionics Cool-
tip RF System (Tyco Healthcare, USA) was used in all cases
and 0.5e1.0 cm around the tumor was ablated in each case.
Multiple overlapping ablations were needed in order to
achieve sufficient coverage with margins. The ablation time
was related to tumor size and proximity to vasculature.
About 20 minutes were taken to produce a 3e5 cm ablation
area. Multiple overlapping ablations were needed in order
to achieve sufficient coverage within margins. The needle
track was burned at the end of the procedure before the
retraction of needle.
Follow-up protocol
Serum total bilirubin (TB), alanine transaminase (ALT), and
albumin (ALB) were evaluated and the ChildePugh score
was determined before the procedure and at three
Table 1 Baseline characteristics of 53 patients who
underwent TACEþRFA for unresectable hepatocellular
carcinoma.
Parameters Value
Number of patients 53
Age, ya 45 (37e78)
Sex (male/female) 46/7
Size of tumor, cma 3.5 (0.8e6.2)
Number of tumora 3 (1e6)
HBV/HCV/both/others 47/4/0/2
ICG-R15, %a 33 (20e46)
Serum bilirubin, mmol/La 18 (5e52)
Serum albumin, g/La 38 (25e47)
ALT (IU/L)a 45 (14e175)
Prothrombin time(s) 13 (9e19)
ChildePugh grade (A/B/C) 36/12/5
ChildePugh scorea 6 (5e11)
Interval between TACE and RFA, da 3 (1e7)
Number of cirrhosis 41
ALT Z alanine aminotransferase; HBV Z hepatitis B virus;
HCV Z hepatitis C virus; ICG-R15 Z indocyanine green
retention at 15 min after intravenous injection; RFA Z
radiofrequency ablation; TACE Z transcatheter arterial
chemoembolization.
a Data were expressed as median (range).
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with RFA (TACEþRFA). Development of ascites, hepatic
encephalopathy or any other comorbidities were recorded.
Aggravation of liver function was defined as ChildePugh
score increasing by two or more after TACEþRFA. Moreover,
Cox proportional hazards regression analysis was used to
clarify risk factors for aggravation of liver function after
TACEþRFA.
Statistical analysis
All statistical analysis were performed using SPSS13.0 for
windows (SPSS, Chicago, IL, USA). Laboratory data are
shown as mean  standard deviation. Cox proportional
hazard regression model was performed to evaluate risk
factors for aggravation of liver function obtained prior to
initial TACE. Univariate analysis evaluated 15 factors: age,
sex, ChildePugh grade, ChildePugh score, tumor size,
tumor number, ICG-R15, TB, ALB, ALT, platelet count,
prolongation of prothrombin time, alpha fetoprotein,
complication, and cirrhosis. Parameters identified as
significant in univariate analysis were tested in the multi-
variate Cox proportional hazard model for all patients. All
reported P values were two-sided and P values < 0.05 were
considered statistically significant.
Results
Changes of liver function parameters before and
after TACEDRFA
Biochemical parameters were shown graphically as mean 
standard deviation in Fig. 1 Plasma TB, ALT and ChildePughscore increased significantly after TACEþRFA procedures
but ALB decreased post-procedurally. TB peaked on post-
procedural day three at 34.1  21.8 mmol/L compared
with a pre-procedural TB of 22.1  12.4 mmol/L
(P Z 0.017). Thereafter, TB dropped steadily to
29.7  18.5 mmol/L after one week and 26.2  14.1 mmol/L
after one month (Fig. 1A). It can be seen that TB could
fall to the reference range within one month after treat-
ment except for two patients suffering from liver failure
and one dying of acute pulmonary embolism. ALT increased
greatly from 65  58 IU/L to 285  182 IU/L post-
procedurally (P Z 0.006) and declined much faster than
any other parameters, but mostly could be within normal
range by week 1e4 (Fig. 1B). ALB was different from ALT
and TB, it dropped from 42.5  4.5 g/L to 34.6  5.4 g/L
(P Z 0.027); ALB less than 30 g/L was discovered in 11
patients in whom we performed human ALB infusion to
achieve temporary increase of ALB, which affected the
ALB change in our study. Therefore, we excluded those 11
patients through the ALB and ChildePugh score analysis.
ALB could reach 34.3  4.1 g/L one month after proce-
dures (Fig. 1C). ChildePugh score was a comprehensive
parameter that could reflect the liver function totally; in
our study ChildePugh score increased from 5.2  1.3 to
7.1  1.5 three days after TACEþRFA (PZ 0.015) and then
decreased to 6.6  1.4 mmol/L after 1 week and
6.2  1.7 mmol/L after one month (Fig. 1D). However, no
significant differences were found in comparison to pre-
procedural ChildePugh scores. Moreover, 13 patients
with two or more increments of ChildePugh score within
one month after procedures were identified during
follow-up.
Complications
Two patients suffered from liver failure within one week
after TACEþFRA, one in ChildePugh grade B and one in
ChildePugh grade C. One patient died of acute pulmonary
embolism after lying in bed for six days post-procedurally.
Five cases developed moderate ascites and two of them
had hydrothorax, which was controlled with conservative
treatment. Minor complications such as abdominal pain,
discomfort in the gastrointestinal tract, and fever (>38C)
were found in 31 patients after TACEþRFA therapies. In
total, 33 patients developed major or minor complications
in our study.
Risk factors for deterioration of liver function after
TACEDRFA
Aggravation of liver function was defined as two or more
increments of ChildePugh score within one month after
TACEþRFA therapy. In addition, Cox proportional hazards
regression analysis was performed to clarify risk factors for
aggravation of liver function after treatment. Fifteen risk
factors were analyzed (Table 2). Univariate analysis showed
ChildePugh score 9 points and age 60 years as the
predictive factors for deterioration of liver function after
TACEþRFA therapy. However, ChildePugh score 9 points
was the only significant risk factor identified by stepwise
multivariate analysis.
Figure 1 Changes of liver function parameters were demonstrated in terms of mean and standard deviation A, The changes of TB
within one month after TACEþRFA. B, The changes of ALT within one month after TACEþRFA. C, The changes of ALB within one
month after TACEþRFA (excluding 11 patients who had ALB infusion performed after procedures). D, The changes of Child-Pugh
score within one month after TACEþRFA (excluding 11 patients who had ALB infusion performed after procedures). Pre Z before
TACE; Day 3 Z 3 days after RFA; Week 1 Z 1 week after RFA; Month 1 Z 1 month after RFA; TB Z plasma total bilirubin; ALT Z
alanine aminotransferase; ALB Z albumin; TACE Z transcatheter arterial chemoembolization; RFA Z radiofrequency ablation.
Table 2 Risk factors contributing to degradation of liver function after TACE and RFA.
Variables (n/n) OR (95% CI) P
Univariate analysis
Age (<60 vs. 60 y) (33/20) 4.23 (0.63e16.46) 0.05
Sex (male vs. female) (46/7) 0.98 (0.09e10.82) 0.81
ChildePugh grade (A vs. B, C) (36/12/5) 0.80 (0.07e8.75) 0.85
ChildePugh score (<9 vs. 9 points) (35/18) 5.53 (1.13e26.92) 0.03
Size of tumor (<3.0 vs. 3.0 cm) (10/43) 2.25 (0.45e5.86) 0.57
Number of tumor (single vs. multiple) (35/18) 0.74 (0.33e1.66) 0.47
ICG-R15 (<30 vs. 30%) (38/15) 0.92 (0.12e7.59) 0.73
TB (<28 vs. 28mmol/L) (46/7) 0.96 (0.11e8.25) 0.83
ALB (<35 vs. 35 g/L) (15/38) 2.75 (0.20e37.37) 0.44
ALT (<55 vs. 55 IU/L) (30/23) 0.79 (0.17e3.64) 0.76
PLT (<100 vs. 100  109/L) (27/26) 1.65 (0.33e8.11) 0.53
Prolongation of PT (<4 vs. 4 s) (43/10) 0.91 (0.14e5.91) 0.92
AFP (<100 vs. 100 ng/ml) (25/28) 0.76 (0.17e3.35) 0.71
Complication (þ vs. ) (33/20) 1.03 (0.14e7.18) 0.91
Cirrhosis (þ vs. ) (36/17) 1.18 (0.24e5.83) 0.83
Multivariate analysis
Age(<60 vs. 60 y) (33/20) 3.07 (0.55e12.35) 0.51
ChildePugh score (<9 vs. 9 points) (35/18) 4.88 (1.59e14.93) 0.005
AFPZ alpha fetoprotein; ALBZ albumin; ALTZ alanine aminotransferase; ORZ Odds Ratio; PLTZ platelet count; PTZ prothrombin
time; TB Z plasma total bilirubin ICG-R15 Z indocyanine green retention at 15 min.
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We investigated how TACE combined with RFA for patients
with hepatocellular carcinoma affected liver function
during a short-term follow-up. Two or more increments of
ChildePugh score was defined as aggravation of liver
function. As a result, our findings demonstrated that
TACEþRFA induced a short-term deterioration of Childe
Pugh score in 25% (13/53) of patients. A previous study had
shown that 9.6% of patients who underwent percutaneous
ethanol injection (PEI) or the combination of PEI and
transcatheter arterial embolization (TAE) developed dete-
rioration of the liver parenchymal function.14 On the
contrary, 34% of patients in the Koda et al study who
underwent RFA or a combination of RFA and TAE had these
deteriorations.15 Therefore, treatments played an impor-
tant role in the development of post-procedural deterio-
ration of liver function.
In our study, TB, ALT and ChildePugh score increased
significantly three days post-procedurally, which was
induced by transient hepatic injury from occlusion of
hepatic arteries and heat ablation of tissue and recovered
slowly within a month after the acute lesion caused by the
therapy. However, ALB decreased post-procedurally, which
may be related to inhibition of ALB synthesis due to several
inflammatory cytokines such as IL-1, IL-6, transforming
necrosis factor alpha, or the loss of liver parenchymal
volume due to TACEþRFA.16,17 Therefore, the inflammation
and the loss of liver volume caused the decrease in serum
ALB within one month while the increase in serum TB was
not related to inflammation.
The deterioration of liver function after TACEþRFA was
frequently found in patients with ChildePugh grade of B or
C pre-procedurally, which accounted for 62% of patients
who demonstrated a deterioration of liver parenchymal
function. Complications such as ascites or hydrothorax also
occurred primarily in patients with a ChildePugh grade of B
or C; this result was compatible with the finding that
a ChildePugh grade of B or C is a risk factor for complica-
tions, as reported by Hoshida et al.18 The above result
indicated that liver function was difficult to recover due to
insufficient hepatic regeneration in advanced cirrhotic
patients. We evaluated 15 factors related to HCC patient,
and a ChildePugh score 9 points was considered to be the
only significant risk factor for deterioration of liver function
identified by stepwise multivariate analysis in our study.
It was reported that the necrotic area from RFA with
vascular occlusion was larger than from RFA alone,19e21 but
RFA combined with vascular occlusion may develop more
severe damages to liver function, which was demonstrated
in Kuroda et al’s study as compared to our study.12 Whether
or not the post-procedural changes of liver function after
TACEþRFA affect long-term liver function and survival,
these patients are needed to undergo a long-term follow-up
period in the future.
In conclusion, TACE combined with RFA induced a tran-
sient deterioration of liver parenchymal function in
patients with a ChildePugh grade of B or C pre-
procedurally. A ChildePugh score 9 points before treat-
ment was a significant risk factor for post-procedural
deterioration of liver function. Therefore, patients witha ChildePugh score 9 points would not be appropriate
candidates for TACEþRFA therapy.References
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